Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Ultragenyx reported a quarterly loss of $1.81 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.23, marking an earnings surprise of -47.15% [1] - The company generated revenues of $159.93 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.55% [2] - The stock has underperformed, losing about 20.4% since the beginning of the year compared to the S&P 500's gain of 16.5% [3] Financial Performance - The loss per share increased from $1.4 a year ago to $1.81 this quarter [1] - Year-over-year revenue growth was observed, with revenues increasing from $139.49 million to $159.93 million [2] - The current consensus EPS estimate for the upcoming quarter is -$1.17 on revenues of $182.02 million, and for the current fiscal year, it is -$5.26 on revenues of $657.62 million [7] Market Outlook - The Zacks Rank for Ultragenyx is currently 3 (Hold), indicating expected performance in line with the market [6] - The Medical - Biomedical and Genetics industry is ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - The trend of earnings estimate revisions is mixed, which could influence future stock performance [6]